1-3 of 3
Xingyue Zong
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Interim Phase I Clinical Data of FT576 As Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma

Binod Dhakal, Jesus G. Berdeja, Tara Gregory, Thomas Ly, Cara Bickers, Xingyue Zong, Lilly Wong, Jode P. Goodridge, Sarah Cooley, Bahram Valamehr, Yu-Waye Chu, John Byon, Rafat Abonour
Journal: Blood
Blood (2022) 140 (Supplement 1): 4586–4587.
https://doi.org/10.1182/blood-2022-166994
Published: 2022
Journal Articles

iPSC-Derived CD38-Null NK Cells in Combination with CD38-Targeted Antibody: A Dual Therapeutic Strategy to Enable ADCC and Eliminate Host Immune Cells in Multiple Myeloma

Rina M Mbofung, Xingyue Zong, Erika Varady, Alan M Williams, Ken L Hayama, Yijia Pan, Sushil Devkota, Brian Groff, Miguel Meza, Thomas Dailey, Tom Lee, Lilly Wong, Sarah Cooley, Ryan Bjordahl, Jode P Goodridge, Bahram Valamehr
Journal: Blood
Blood (2022) 140 (Supplement 1): 7388–7389.
https://doi.org/10.1182/blood-2022-169817
Published: 2022
Journal Articles

A Phase I Study of FT538, an Off-the-Shelf, Multiplexed-Engineered, iPSC-Derived NK Cell Therapy in Combination with Daratumumab in Relapsed/Refractory Multiple Myeloma

Mark Juckett, Sham Mailankody, Alireza Eghtedar, Cara Bickers, Xingyue Zong, Lilly Wong, Thomas Ly, John Byon, Sarah Cooley, Bahram Valamehr, Yu-Waye Chu, Ravi Vij
Journal: Blood
Blood (2022) 140 (Supplement 1): 10327–10328.
https://doi.org/10.1182/blood-2022-166728
Published: 2022